• Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
    • Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The PERSPECTIVE I&I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y.
    • J Pers Med. 2021 Jul 27;11(8):726. doi: 10.3390/jpm11080726.
    • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
    • Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The PERSPECTIVE I&I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y.
    • J Pers Med. 2021 Jul 27;11(8):726. doi: 10.3390/jpm11080726.
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi, N Barata, P Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021;5:1200. doi: 10.1200/PO.21.00070. Epub 2021 Jul 22.
    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kubiak TK, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Antoine Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
    • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
    • Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The PERSPECTIVE I&I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y.
    • J Pers Med. 2021 Jul 27;11(8):726. doi: 10.3390/jpm11080726.
    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kubiak TK, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Antoine Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
  • LitAlert ~~ GeneLit.com

    • Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
    • Hobbs EA, Litton JK, Yap TA.
    • Expert Opin Pharmacother. 2021 Jul 26:1-13. doi: 10.1080/14656566.2021.1952181. Epub ahead of print.
    • Review
    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    • Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM.
    • Oncol Ther. 2021 Jul 25. doi: 10.1007/s40487-021-00162-4. Epub ahead of print.
    • Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    • Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L, Pavone M, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00587-4. doi: 10.1016/j.ygyno.2021.07.025. Epub ahead of print.
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi, N Barata, P Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021;5:1200. doi: 10.1200/PO.21.00070. Epub 2021 Jul 22.
    • Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis.
    • Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M.
    • Front Oncol. 2021 Jul 19;10:638295. doi: 10.3389/fonc.2021.638295.
  • LitAlert ~~ GeneLit.com

    • Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
    • Hobbs EA, Litton JK, Yap TA.
    • Expert Opin Pharmacother. 2021 Jul 26:1-13. doi: 10.1080/14656566.2021.1952181. Epub ahead of print.
    • Review
    • Rapid progression of metastatic pancreatic adenocarcinoma during platinum-based therapy in a patient harboring a pathogenic BRCA2 germline variant.
    • Sorscher S, Ramkissoon S.
    • Oncologist. 2021 Jul 26. doi: 10.1002/onco.13912. Epub ahead of print.
    • A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status.
    • Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, Murphy BR, Singhal PK, McCrea C, Shinde R, Briceno JM.
    • Oncol Ther. 2021 Jul 25. doi: 10.1007/s40487-021-00162-4. Epub ahead of print.
    • Optimizing the number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma: A propensity-score matching analysis.
    • Marchetti C, Rosati A, De Felice F, Boccia SM, Vertechy L, Pavone M, Palluzzi E, Scambia G, Fagotti A.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00587-4. doi: 10.1016/j.ygyno.2021.07.025. Epub ahead of print.
    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00591-6. doi: 10.1016/j.ygyno.2021.07.029. Epub ahead of print.
    • The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, Nam EJ, Lim MC.
    • Gynecol Oncol. 2021 Jul 22:S0090-8258(21)00590-4. doi: 10.1016/j.ygyno.2021.07.028. Epub ahead of print.
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi, N Barata, P Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021;5:1200. doi: 10.1200/PO.21.00070. Epub 2021 Jul 22.
    • Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program.
    • Minnier J, Rajeevan N, Gao L, Park B, Pyarajan S,Spellman P; VA Million Veteran Program; Haskell SG, Brandt CA, Luoh SW.
    • JCO Precis Oncol. 2021;5:1178. doi: 10.1200/PO.20.00541. Epub 2021 Jul 21.
    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kubiak TK, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Antoine Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
    • Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    • Sohn MH, Kim SI, Shin JY, Kim HS, Chung HH, Kim JW, Lee M, Seo JS.
    • Genes (Basel). 2021 Jul 20;12(7):1103. doi: 10.3390/genes12071103.
    • Efficacy and safety of PARP inhibitor combination therapy in recurrent ovarian cancer: a systematic review and meta-analysis.
    • Ren N, Zhang L, Yu J, Guan S, Dai X, Sun L, Ying M.
    • Front Oncol. 2021 Jul 19;10:638295. doi: 10.3389/fonc.2021.638295.
  • LitAlert ~~ GeneLit.com

    • What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    • Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A, Mishra GD.
    • Gynecol Oncol. 2021 Jul 23:S0090-8258(21)00591-6. doi: 10.1016/j.ygyno.2021.07.029. Epub ahead of print.
    • The preventive effect of breastfeeding against ovarian cancer in BRCA1 and BRCA2 mutation carriers: A systematic review and meta-analysis.
    • Eoh KJ, Park EY, Chang YJ, Ha HI, Hong J, Huang D, Nam EJ, Lim MC.
    • Gynecol Oncol. 2021 Jul 22:S0090-8258(21)00590-4. doi: 10.1016/j.ygyno.2021.07.028. Epub ahead of print.
    • Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer.
    • Taza F, Holler AE, Fu W, Wang H, Adra N, Albany C, Ashkar R, Cheng HH, Sokolova AO, Agarwal N, Kessel A, Bryce A, Nafissi, N Barata, P Sartor AO, Bastos D, Smaletz O, Berchuck JE, Taplin ME, Aggarwal R, Sternberg CN, Vlachostergios PJ, Alva AS, Su C, Marshall CH, Antonarakis ES.
    • JCO Precis Oncol. 2021;5:1200. doi: 10.1200/PO.21.00070. Epub 2021 Jul 22.
    • No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.
    • Imbert-Bouteille M, Corsini C, Picot MC, Mizrahy L, Akouete S, Huguet H, Thomas F, Geneviève D, Taourel P, Ychou M, Galibert V, Rideau C, Baudry K, Kubiak TK, Coupier I, Hobeika R, Macary Y, Toledano A, Solassol J, Antoine Maalouf A, Daures JP, Pujol P.
    • Genes (Basel). 2021 Jul 20;12(7):1100. doi: 10.3390/genes12071100.
  • LitAlert ~~ GeneLit.com

    • Risk-Stratified Approach to Breast Cancer Screening in Canada: Women’s Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
    • Alarie S, Hagan J, Dalpé G, Faraji S, Mbuya-Bienge C, Nabi H, Pashayan N, Brooks JD, Dorval M, Chiquette J, Eloy L, Turgeon A, Lambert-Côté L, Paquette JS, Walker MJ, Lapointe J, Granados Moreno P, Blackmore K, Wolfson M, Broeders M, The PERSPECTIVE I&I Study Group, Knoppers BM, Chiarelli AM, Simard J, Joly Y.
    • J Pers Med. 2021 Jul 27;11(8):726. doi: 10.3390/jpm11080726.
    • Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program.
    • Minnier J, Rajeevan N, Gao L, Park B, Pyarajan S,Spellman P; VA Million Veteran Program; Haskell SG, Brandt CA, Luoh SW.
    • JCO Precis Oncol. 2021;5:1178. doi: 10.1200/PO.20.00541. Epub 2021 Jul 21.